glp 1 risk of cancer Long-term in users GLP-1 agonists in Denmark: a nationwide emulated trial Glucagon-like peptide 1 receptor agonists

Important Note: Peptides are powerful biologic messengers that must be used under practitioner supervision

While many associate B12 deficiency with poor nutrition, a significant number of cases are due to non-dietary causes, such as Pernicious Anaemia

Key limitations of current evidence include: Relatively short follow-up periods (typically 35 years) in randomised trials, whereas pancreatic cancer may take years to develop Potential for detection bias, as patients on GLP-1 therapy may undergo more frequent medical monitoring Difficulty accounting for all confounding factors in observational studies Despite these limitations, the weight of current evidence does not support a causal link between GLP-1 receptor agonist use and pancreatic cancer development

Tektons centralized services team delivered swift regulatory turnaround in under 24 hours, eliminating delays and enabling the site to begin screening and enrollment almost immediately